Trial Profile
A 5 year post-marketing study of dalfampridine extended release in patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2016
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 17 Feb 2016 New trial record